{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-024605","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.215405+00:00","generated_at":"2026-06-24T22:22:04.216187+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Trevi Therapeutics reports positive Phase 2b/3 PRISM trial for Haduvio in prurigo nodularis","bullets":["Primary endpoint met: 25% of Haduvio subjects achieved 4-point WI-NRS reduction vs 14% placebo (p=0.0157).","Significant improvement in ItchyQoL (p=0.0002) and Prurigo Activity Scale (p=0.006) at week 14.","Safety profile consistent with prior trials; discontinuations 36.9% Haduvio vs 19.3% placebo.","Cash and investments expected ~$78M at June 30, 2022; plans to discuss data with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-024605","json":"https://secwatch.observer/filing/0001564590-22-024605.json","markdown":"https://secwatch.observer/filing/0001564590-22-024605.md","text":"https://secwatch.observer/filing/0001564590-22-024605.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022024605/0001564590-22-024605-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022024605/trvi-8k_20220629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:22:04.216187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}